Hematopoietic Stem Cell Transplantation in Thalassemia and Sickle Cell Disease
Author Information
Author(s): Marco Marziali, Antonella Isgrò, Javid Gaziev, Guido Lucarelli
Primary Institution: International Center for Transplantation in Thalassemia and Sickle Cell Anemia, Mediterranean Institute of Hematology, Rome- Italy
Hypothesis
Can hematopoietic stem cell transplantation (HSCT) effectively treat thalassemia and sickle cell disease in a multi-ethnic population?
Conclusion
HSCT is a viable and effective treatment for thalassemia and sickle cell disease, showing high survival rates in well-selected patients.
Supporting Evidence
- HSCT has shown improved results over the last two decades due to better preventive strategies.
- Patients with thalassemia and sickle cell anemia have a high risk of graft rejection due to sensitization.
- Class 1 patients have a very high probability of cure with low morbidity and mortality.
Takeaway
Doctors can help kids with thalassemia and sickle cell disease by giving them special cells from a donor, which can make them healthy again.
Methodology
145 patients with thalassemia and sickle cell anemia received HSCT, with a focus on ethnic diversity and sensitization risks.
Potential Biases
Potential bias due to the ethnic diversity of the patient population and varying pre-transplant conditions.
Limitations
The study may not fully account for the long-term effects of HSCT and the specific challenges faced by highly sensitized patients.
Participant Demographics
Patients were ethnically heterogeneous from Mediterranean and Middle East countries, with a majority not regularly transfused.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website